Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Opdualag Approved to Treat Advanced Melanoma - NCI

The Efficacy and Safety of Immune Checkpoint Inhibitors in Treating Melanoma

Updated Data for First-Line Immunotherapy Combinations Reinforce Their Value in Metastatic Melanoma

Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the Brain

Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses

Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study - ScienceDirect

Ipilimumab plus nivolumab in patients with symptomatic melanoma brain metastasis requiring corticosteroids - ScienceDirect

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

Cancers, Free Full-Text